Healx has commenced its Phase I/II dose-escalation and dose-confirmation clinical trial to evaluate the safety and efficacy of HLX-4310 in adolescents and adults with relapsed, refractory sarcoma, with a focus on osteosarcoma. HLX-4310 is an investigational oral combination of a class I selective HDAC inhibitor and an… Read More
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to a treatment for osteosarcoma. SOT106, developed by biopharmaceutical company SOTIO Biotech, is a next-generation antibody-drug conjugate (ADC) targeting leucine-rich repeat-containing 15 (LRRC15), a clinically validated target broadly expressed across sarcoma subtypes and in tumour associated stroma. Preclinical data… Read More
Introduction In an age where novel biotechnology products are being developed on a much larger and more rapid scale at significantly higher costs and risks than ever before, it is important that this urgency is maintained through to patient access. Owing to the broad reach and the mass… Read More
Introduction Rare diseases, as classified by the FDA and EMA, are conditions that affect fewer than 200,00 people in the US1 or fewer than five in 10,000 people in the EU2. Because of these small populations, rare diseases often face unique – and some respects potentially… Read More
How can we leverage canine osteosarcoma to validate biomarkers and accelerate the pathway to new therapies? Integration of comparative biology, specifically the study of naturally occurring cancers in companion animals (primarily dogs) known as comparative oncology, over the last three decades has significantly transformed cancer research… Read More
An overview of osteosarcoma epidemiology and treatment landscape to guide the future of therapeutic intervention. Osteosarcoma is a rare, aggressive form of bone cancer primarily affecting children and young adults. It is well recognised there continues to exist a critical unmet need in paediatric oncology due… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, research into bacterial species and diseases broke new ground. Elsewhere, vaccines could… Read More
News round-up for 17 – 21 November by Bruno Quinney, Content Team at DDW. This week in DDW, research into bacterial species and diseases gets top billing. Elsewhere, vaccines could offer groundbreaking solutions to cervical and lung cancer. The top stories: Medication detrimental to gut microbiome,… Read More
The Osteosarcoma Institute (OSI) has awarded over $1.5 million in research funding to four projects aiming to advance the treatment of osteosarcoma. The OSI, which works to increase treatment options and survival rates in osteosarcoma patients, has awarded sums between $125,000 and $500,000 to projects in the field. … Read More
OS Therapies has shared positive clinical trial data updates from its Phase IIb clinical trial of immunotherapy candidate OST-HER2 in fully resected, lung metastatic osteosarcoma. The data were presented by Principal Investigator Dr Damon Reed at the MIB Factor Osteosarcoma Conference held in Salt Lake City, Utah… Read More
CureSearch for Children’s Cancer has awarded a $1.5 million grant to Dr Patrick Grohar of Children’s Hospital of Philadelphia to develop a new targeted treatment approach for paediatric osteosarcoma, an aggressive form of bone cancer. The award – the Fight Osteosarcoma Together Super Grant – is a… Read More
